i
|
Ri
b
|
p-y in Si
c
|
Casesd
|
LRTe
|
ERR1
f
|
---|
1
|
0 – 0.01552
|
1522195.93
|
441
|
22.00
|
1.67
|
2
|
0.015521 – 0.019389
|
1520822.41
|
459
|
18.94
|
1.28
|
3
|
0.19396 – 0.022682
|
1521452.84
|
499
|
27.01
|
1.49
|
4
|
0.022687 – 0.025616
|
1521872.88
|
500
|
30.31
|
1.57
|
5
|
0.025619 – 0.30046
|
1521932.58
|
510
|
28.61
|
1.42
|
6
|
0.030066 – 0.037161
|
1522215.36
|
494
|
26.14
|
1.37
|
7
|
0.037211 – 0.87187
|
1521303.24
|
483
|
26.31
|
1.50
|
8
|
0.87209 – 0.97152
|
1521034.77
|
492
|
30.44
|
1.36
|
9
|
0.97154 – 1.0107
|
1521559.95
|
507
|
28.56
|
1.74
|
10
|
1.0108 – 2.000
|
1519135.79
|
475
|
26.42
|
1.21
|
-
aThe two-phase and linear models are fitted to subsets of the 0 – 20 mSv liver data with latency φ = 36.90 years (optimal for the two-phase model on the 0 – 20 mSv data, see Table 3)
-
bRi is the excluded dose range (in 10 mSv units). Si consists of those cells in the 0 – 20 mSv subcohort whose weighted adjusted colon dose does not fall in Ri
-
cPerson-years in Si
-
dCases (liver cancer deaths) in Si
-
eLRT = LRT2p-lin for comparing the two-phase model with the linear model when fitted to Si with latency φ = 36.90 years
-
fERR1 is the estimated Excess Relative Risk at 10 mSv when the two-phase model with latency φ = 36.90 years is fitted to Si